Daniel I Martín-Jiménez

Dr. Daniel I Martín-Jiménez

Hospital Universitario Virgen Macarena, Seville, Spain
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
María Amparo Callejón LeblicMaría Amparo Callejón Leblic
María Amparo Callejón Leblic
Ramon Moreno-LunaRamon Moreno-Luna
Ramon Moreno-Luna
Alfonso Del Cuvillo BernalAlfonso Del Cuvillo Bernal
Alfonso Del Cuvillo Bernal
ISABEL M REYES-TEJEROISABEL M REYES-TEJERO
ISABEL M REYES-TEJERO
MGMiguel A Garcia-Villaran
Miguel A Garcia-Villaran
Serafín Sánchez-GómezSerafín Sánchez-Gómez
Serafín Sánchez-Gómez
The COVID-19 outbreak has spread extensively around the world. Loss of smell and taste have emerged as main predictors for COVID-19. The objective of our study is to develop a comprehensive machine learning (ML) modelling framework to assess the predictive value of smell and taste disorders, along with other symptoms, in COVID-19 infection. A multicenter case-control study was performed, in which suspected cases for COVID-19, who were tested by real-time reverse-transcription polymerase chain reaction (RT-PCR), informed about the presence and severity of their symptoms using visual analog scales (VAS). ML algorithms were applied to the collected data to predict a COVID-19 diagnosis using a 50-fold cross-validation scheme by randomly splitting the patients in training (75%) and testing datasets (25%). A total of 777 patients were included. Loss of smell and taste were found to be the symptoms with higher odds ratios of 6.21 and 2.42 for COVID-19 positivity. The ML algorithms applied reached an average accuracy of 80%, a sensitivity of 82%, and a specificity of 78% when using VAS to predict a COVID-19 diagnosis. This study concludes that smell and taste disorders are accurate predictors, with ML algorithms constituting helpful tools for COVID-19 diagnostic prediction.

17 August 2022 in Life
Verified
Journal Article
Open access
PDF file
María Amparo Callejón LeblicMaría Amparo Callejón Leblic
María Amparo Callejón Leblic
Daniel I Martín-JiménezDaniel I Martín-Jiménez
Daniel I Martín-Jiménez
Ramon Moreno-LunaRamon Moreno-Luna
Ramon Moreno-Luna
JPJose Palacios-García
Jose Palacios-García
MAMarta Alvarez-Cendrero
Marta Alvarez-Cendrero
Serafín Sánchez-GómezSerafín Sánchez-Gómez
Serafín Sánchez-Gómez
Background: Although smell and taste disorders are highly prevalent symptoms of COVID-19 infection, the predictive factors leading to long-lasting chemosensory dysfunction are still poorly understood. Methods: 102 out of 421 (24.2%) mildly symptomatic COVID-19 patients completed a second questionnaire about the evolution of their symptoms one year after the infection using visual analog scales (VAS). A subgroup of 69 patients also underwent psychophysical evaluation of olfactory function through UPSIT. Results: The prevalence of chemosensory dysfunction decreased from 82.4% to 45.1% after 12 months, with 46.1% of patients reporting a complete recovery. Patients older than 40 years (OR = 0.20; 95% CI: [0.07, 0.56]) and with a duration of loss of smell longer than four weeks saw a lower odds ratio for recovery (OR = 0.27; 95% CI: [0.10, 0.76]). In addition, 28 patients (35.9%) reported suffering from parosmia, which was associated with moderate to severe taste dysfunction at the baseline (OR = 7.80; 95% CI: [1.70, 35.8]). Among the 69 subjects who underwent the UPSIT, 57 (82.6%) presented some degree of smell dysfunction, showing a moderate correlation with self-reported VAS (r = −0.36, p = 0.0027). Conclusion: A clinically relevant number of subjects reported persistent chemosensory dysfunction and parosmia one year after COVID-19 infection, with a moderate correlation with psychophysical olfactory tests.

30 August 2023 in Current Allergy and Asthma Reports
Verified
Journal Article
Closed access
PDF file
JMJuan Maza-Solano
Juan Maza-Solano
ACAmparo Callejon-Leblic
Amparo Callejon-Leblic
Daniel I Martín-JiménezDaniel I Martín-Jiménez
Daniel I Martín-Jiménez
RMRamon Moreno-Luna
Ramon Moreno-Luna
JGJaime Gonzalez-Garcia
Jaime Gonzalez-Garcia
SSSerafin Sanchez-Gomez
Serafin Sanchez-Gomez

1 February 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Daniel I Martín-JiménezDaniel I Martín-Jiménez
Daniel I Martín-Jiménez
Ramon Moreno-LunaRamon Moreno-Luna
Ramon Moreno-Luna
María Amparo Callejón LeblicMaría Amparo Callejón Leblic
María Amparo Callejón Leblic
Alfonso Del Cuvillo BernalAlfonso Del Cuvillo Bernal
Alfonso Del Cuvillo Bernal
CECharles S Ebert
Charles S Ebert
Serafín Sánchez-GómezSerafín Sánchez-Gómez
Serafín Sánchez-Gómez
(1) Background: Surgical criteria for chronic rhinosinusitis with nasal polyps (CRSwNP) remain unresolved. This study addresses these discrepancies by comparing the clinical outcomes of expanded–functional endoscopic sinus surgeries (E–FESS) with more-limited FESS (L-FESS). (2) Methods: A database was analyzed retrospectively to compare surgical outcomes in CRSwNP patients who underwent E-FESS versus those subjected to L-FESS. Quality of life, endoscopic and radiological outcomes were compared at the baseline and two years after surgery. The clinical status of the responder was defined when a minimal clinically important difference of 12 points in SNOT-22 change was achieved. (3) Results: A total of 274 patients met the inclusion criteria and were analyzed; 111 underwent E-FESS and 163 were subjected to L-FESS. Both groups exhibited significant clinical improvements, although a greater magnitude of change in SNOT-22 (14.8 ± 4.8, p = 0.002) was shown after E-FESS. Higher significant improvements for endoscopic and radiological scores and lower surgical revision rates were also noted in the E-FESS group. (4) Conclusions: E-FESS provides better clinical outcomes and reduced revision surgery rates when compared to L-FESS in CRSwNP patients two years after surgery, irrespective of any comorbidity. Further randomized prospective studies are needed to comprehensively contrast these results.

16 January 2024 in International Forum of Allergy & Rhinology
Verified
Journal Article
Closed access
Daniel I Martín-JiménezDaniel I Martín-Jiménez
Daniel I Martín-Jiménez
Ramon Moreno-LunaRamon Moreno-Luna
Ramon Moreno-Luna
María Amparo Callejón LeblicMaría Amparo Callejón Leblic
María Amparo Callejón Leblic
Alfonso Del Cuvillo BernalAlfonso Del Cuvillo Bernal
Alfonso Del Cuvillo Bernal
CECharles S. Ebert
Charles S. Ebert
Serafín Sánchez-GómezSerafín Sánchez-Gómez
Serafín Sánchez-Gómez

10 October 2024 in European Annals of Otorhinolaryngology, Head and Neck Diseases
Verified
Journal Article
Closed access
Daniel I Martín-JiménezDaniel I Martín-Jiménez
Daniel I Martín-Jiménez
Ramon Moreno-LunaRamon Moreno-Luna
Ramon Moreno-Luna
CGC. Gago-Torres
C. Gago-Torres
Juan Maza-SolanoJuan Maza-Solano
Juan Maza-Solano
Serafín Sánchez-GómezSerafín Sánchez-Gómez
Serafín Sánchez-Gómez